Tag Archives: Adaptimmune

Immunocor’s Anti-Cancer Platform Garners $320MM Private Financing

Immunocor raised $320MM in a private financing round to support its anti-cancer platform. That’s a lot of money for a single financing – in fact, it is the largest private fundraising by a European biotechnology company. What’s the attraction? Continue reading

Unum’s Antibody-Directed T Cells: Differentiated from CAR T-Cell and T Cell Receptor Reprogramming

Unum Therapeutics is a new immunotherapy biotechnology company in which Fidelity Biosciences, Atlas Ventures and Sanofi invested $12 MM in a Series A (first venture round) of investment. Continue reading